Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease
Candrilli, S., O'Brien, S. H., Ware, R. E., Nahata, M. C., Seiber, E. E., & Balkrishnan, R. (2011). Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease. American Journal of Hematology, 86(3), 273-277.
While laboratory and clinical benefits of hydroxyurea for patients with sickle cell disease (SCD) are well-established, few data describe the extent and implications of non-adherence. We sought to assess adherence to hydroxyurea among patients with SCD and investigate associations between adherence and clinical and economic outcomes. Insurance claims of North Carolina Medicaid enrollees (6/2000-8/ 2008) with SCD were analyzed. Inclusion criteria included age <65 years, continuous Medicaid enrollment >= 12 months before and following hydroxyurea initiation, and >= 2 hydroxyurea prescriptions. Three hundred twelve patients, mean age 21 (+/- 12.2) years, met inclusion criteria and 35% were adherent, defined as a medication possession ration (MPR) >= 0.80; mean MPR was 0.60. In the 12 months following hydroxyurea initiation, adherence was associated with reduced risk of SCD-related hospitalization (hazard ratio [HR] = 0.65, p = .0351), all-cause and SCD-related emergency department visit (HR = 0.72, p = .0388; HR = 0.58, p = .0079, respectively), and vaso-occlusive event (HR = 0.66, p = .0130). Adherence was associated with reductions in health care costs such as all-cause and SCD-related inpatient (-$ 5,286, p < .0001; -$4,403, p < .0001, respectively), ancillary care (-$1,336, p < .0001; -$836, p < .0001, respectively), vaso-occlusive event-related (-$5,793, p < .0001), and total costs (-$6,529, p < .0001; -$5,329, p < .0001, respectively). Adherence to hydroxyurea among SCD patients appears suboptimal and better adherence is associated with improved clinical and economic outcomes. Am. J. Hematol. 86:273-277, 2011. (C) 2010 Wiley-Liss, Inc